Jefferies Financial Group Inc. Acquires 344,200 Shares of Heron Therapeutics, Inc. $HRTX

Jefferies Financial Group Inc. boosted its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 106.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 666,800 shares of the biotechnology company’s stock after buying an additional 344,200 shares during the period. Jefferies Financial Group Inc. owned approximately 0.44% of Heron Therapeutics worth $1,380,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth $691,000. Congress Park Capital LLC increased its holdings in Heron Therapeutics by 11.4% during the 2nd quarter. Congress Park Capital LLC now owns 2,268,249 shares of the biotechnology company’s stock worth $4,695,000 after purchasing an additional 232,632 shares in the last quarter. Informed Momentum Co LLC bought a new position in Heron Therapeutics during the 1st quarter worth about $768,000. AIGH Capital Management LLC raised its stake in shares of Heron Therapeutics by 8.3% in the 2nd quarter. AIGH Capital Management LLC now owns 3,009,257 shares of the biotechnology company’s stock valued at $6,229,000 after purchasing an additional 231,057 shares during the period. Finally, TD Asset Management Inc bought a new stake in shares of Heron Therapeutics in the first quarter valued at about $868,000. Institutional investors own 80.01% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on HRTX. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Wall Street Zen lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Heron Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $1.12 on Thursday. The company has a fifty day moving average price of $1.21 and a two-hundred day moving average price of $1.58. Heron Therapeutics, Inc. has a one year low of $1.00 and a one year high of $2.68. The stock has a market cap of $205.37 million, a P/E ratio of -56.00 and a beta of 1.30.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $38.21 million for the quarter, compared to the consensus estimate of $39.03 million. Heron Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.